Dostarlimab dan Kemoterapi Memperpanjang Waktu Terapi Subsekuen pada Kanker Endometrium

• Dostarlimab plus chemotherapy shows effectiveness for older patients with endometrial cancer.
• Results indicate significant increase in TFST and TSST with dostarlimab treatment.
• Even older patients (70+) see marked improvements in treatment duration.

Dostarlimab Plus Chemo Shows Promising Results in Older Patients

Dostarlimab, when combined with chemotherapy, demonstrates significant benefits for patients aged 70 years and older diagnosed with endometrial cancer. In a recent analysis of the phase 3 ENGOT-EN6-NSGO/GOG-3031/RUBY trial, the results clearly indicate that this combination therapy not only prolongs the time to first subsequent therapy (TFST) but also the time to second subsequent therapy (TSST), irrespective of the patient’s age. Specifically, the results showed that the median TFST increased notably from 10.2 months with the placebo regimen to 15.3 months with dostarlimab, suggesting a favorable response in older patients.

Significant Improvements in Time to Therapy Outcomes

Among older patients, those aged 70 years or older benefitted particularly well from the dostarlimab regimen, which prolonged TFST by an impressive 8.7 months compared to placebo. The TSST also saw improvements, extending a remarkable 8.0 months. Interestingly, younger patients under 70 years also saw benefits, but the gains were more pronounced for older patients. The findings emphasize that dostarlimab in combination with carboplatin and paclitaxel provides a solid treatment option across different age groups, delivering efficacy and tolerability well beyond the 3-year follow-up period. Time to treatment outcomes certainly highlight the drug’s potential as a new standard in care.

Safety Profile of Dostarlimab: A Closer Look

In examining safety across age groups, adverse effects were reported for all patients. However, the overall safety profile remained favorable even among older patients, despite a slight increase in serious events. Notably, adverse effects related to immune responses were somewhat higher in the 70-plus age group, indicating a need for close monitoring. Overall, despite some upticks in adverse effects in the older subgroup, the benefits of dostarlimab alongside safety considerations make it an attractive first-line option for older adults facing advanced or recurrent endometrial cancer. The findings appear to solidify dostarlimab’s role, enough to warrant focus on both its efficacy and safety parameters tied to age.

The findings from this analysis affirm that dostarlimab combined with chemotherapy safely and effectively extends the time before subsequent treatments for patients with advanced endometrial cancer of all ages. The advantages in therapy time are especially marked in patients aged 70 and over. Hence, these results strongly support the use of this treatment combination as a standard care protocol.